Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Retinal tissue knockout to study efflux of cholesterol (AGCA1/G1 double KO - TY and LysM cre) - part II (Study ST000682)

C18 NEGATIVE ION MODE (Analysis AN001050)

Metabolite	Structure	F1	F2	F3	F4	F5
plasmenyl-PE 38:2; [M-H]-@7.75	ME189907	0.75	1.82	0.31	0.91	0.96
PS 42:9; [M-H]-@5.05	ME189897	2.08	0.83	0.32	0.83	0.84
FFA(18:2)	ME189807	2.13	0.75	0.61	0.50	1.04
FFA(20:2)	ME189810	2.14	0.87	0.50	0.51	0.98
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.80	ME189818	2.20	0.96	0.48	0.48	0.94
PC 36:6; [M-Ac-H]-@5.40	ME189835	0.82	0.64	1.76	1.07	1.03
FFA(24:0)	ME189816	1.51	0.48	0.53	1.13	1.02
PS 44:11; [M-H]-@4.88	ME189899	1.38	0.57	0.54	1.00	1.14
FFA(20:4) Arachidonic acid	ME189811	1.51	0.79	0.62	0.61	1.24
PE 38:3; [M-H]-@7.19	ME189858	1.55	0.71	0.64	0.66	1.21
plasmenyl-PE 38:3; [M-H]-@7.49	ME189908	1.53	0.73	0.64	0.66	1.22
FFA(22:1)	ME189813	1.63	0.76	0.43	0.68	1.18
PC 40:5; [M-Ac-H]-@6.91	ME189843	1.66	0.62	0.47	0.63	1.27
PE 40:5; [M-H]-@7.04	ME189860	1.65	0.58	0.59	0.71	1.21
FFA(18:1)	ME189806	1.73	0.90	0.63	0.54	1.12
FFA(20:1)	ME189809	1.67	0.86	0.71	0.55	1.14
lysoPE 18:0; [M-H]-@2.44	ME189901	1.90	0.78	0.63	0.67	1.00
FFA(22:3)	ME189815	1.92	0.81	0.45	0.56	1.11
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.37	ME189819	1.85	0.89	0.53	0.56	1.08
PG 36:3; [M-H]-@5.62	ME189872	1.67	0.76	0.86	0.88	0.91
PC 38:3; [M-Ac-H]-@7.04	ME189838	1.62	0.68	0.90	0.78	1.04
PG 44:11; [M-H]-@4.73	ME189882	1.58	0.69	0.86	0.66	1.15
CL 72:4; [M-2H](2-)@9.62	ME189801	1.24	0.99	0.93	0.75	1.08
PC 38:7; [M-Ac-H]-@5.59	ME189840	1.22	0.93	0.71	0.94	1.04
FFA(22:2)	ME189814	1.42	0.94	0.85	0.81	1.00
FFA(24:2)	ME189817	1.40	0.99	0.79	0.94	0.91
PG 40:7; [M-H]-@5.16	ME189879	1.38	1.00	0.70	0.94	0.93
PS 42:10; [M-H]-@4.78	ME189894	1.08	0.71	0.95	0.89	1.20
PC 33:1; [M-Ac-H]-@6.36	ME189826	1.16	0.77	0.88	0.75	1.25
PE 38:2; [M-H]-@7.46	ME189857	1.14	0.77	0.85	0.83	1.21
PC 32:1; [M-Ac-H]-@6.00	ME189824	1.29	0.94	0.72	0.77	1.13
PC 28:0; [M-Ac-H]-@5.19	ME189820	1.21	0.92	0.73	0.73	1.21
PS 34:1; [M-H]-@5.99	ME189886	1.28	0.85	0.77	0.73	1.19
plasmenyl-PE 34:0; [M-H]-@7.40	ME189903	1.23	0.78	0.74	0.82	1.20
PS 40:7; [M-H]-@5.32	ME189893	1.18	0.79	0.62	0.79	1.26
PE 36:3; [M-H]-@6.46	ME189852	1.39	0.82	0.86	0.77	1.10
FFA(20:0)	ME189808	1.49	0.75	0.81	0.78	1.10
FFA(22:0)	ME189812	1.51	0.74	0.85	0.80	1.06
PC 31:0; [M-Ac-H]-@6.20	ME189823	1.34	0.73	0.67	0.72	1.25
PC 42:10; [M-Ac-H]-@5.66	ME189845	1.35	0.74	0.73	0.86	1.13
PG 38:5; [M-H]-@5.54	ME189876	1.37	0.74	0.78	0.80	1.15
PS 40:4; [M-H]-@6.42	ME189891	1.41	0.76	0.80	0.65	1.23
FFA(16:0)	ME189804	1.44	0.72	0.77	0.74	1.17
FFA(18:0)	ME189805	1.42	0.74	0.76	0.73	1.18
PE 37:4; [M-H]-@6.63	ME189855	1.13	1.36	0.84	0.98	0.81
plasmenyl-PE 36:2; [M-H]-@7.24	ME189906	1.06	1.32	0.91	0.90	0.91
PE 44:10; [M-H]-@6.30	ME189865	0.89	1.18	0.90	1.11	0.91
PE 34:3; [M-H]-@5.99	ME189850	0.97	1.35	0.65	0.91	0.99
PG 34:2; [M-H]-@5.42	ME189869	0.94	1.33	0.72	1.00	0.94
PC 33:0; [M-Ac-H]-@6.80	ME189825	0.95	1.20	0.85	0.94	1.01
plasmenyl-PE 34:2; [M-H]-@6.65	ME189905	0.99	1.20	0.72	1.07	0.93
PE 32:0; [M-H]-@6.67	ME189849	1.04	1.11	0.68	1.00	1.00
PS 38:6; [M-H]-@5.21	ME189890	0.94	1.14	0.70	1.02	1.02
PC 36:1; [M-Ac-H]-@7.15	ME189831	0.88	0.99	1.03	1.06	1.01
PC 34:1; [M-Ac-H]-@6.56	ME189827	0.87	1.05	1.02	1.00	1.04
PC 36:2; [M-Ac-H]-@6.72	ME189832	0.94	1.04	1.01	0.97	1.03
PC 39:6; [M-Ac-H]-@6.40	ME189841	0.80	1.05	0.89	1.11	1.02
PS 38:4; [M-H]-@5.93	ME189889	0.82	1.10	0.92	1.03	1.04
PI 38:4; [M-H]-@5.85	ME189885	0.92	1.08	0.85	1.05	1.00
PC 36:0; [M-Ac-H]-@7.66	ME189830	0.91	1.03	0.90	1.01	1.05
PC 38:1; [M-Ac-H]-@7.74	ME189836	0.88	1.03	0.93	0.98	1.07
plasmenyl-PE 34:1; [M-H]-@7.06	ME189904	0.86	1.03	0.86	0.86	1.19
plasmenyl-PE 40:4; [M-H]-@7.62	ME189909	0.94	0.96	1.01	0.94	1.10
PE 38:1; [M-H]-@7.83	ME189856	0.98	0.98	0.91	0.88	1.14
PE 40:4; [M-H]-@7.33	ME189859	0.98	1.02	0.93	0.91	1.08
PG 38:4; [M-H]-@6.01	ME189875	0.96	1.00	0.92	0.92	1.10
CL 72:5; [M-2H](2-)@9.47	ME189802	1.15	0.85	1.06	0.89	1.07
PC 34:2; [M-Ac-H]-@6.17	ME189828	1.08	0.90	1.06	0.92	1.06
PG 36:4; [M-H]-@5.41	ME189873	1.02	0.98	0.87	1.11	0.95
PG 36:2; [M-H]-@5.94	ME189871	1.00	0.83	1.03	1.12	0.98
PG 42:10; [M-H]-@4.64	ME189881	1.11	0.87	0.94	0.97	1.05
PC 35:1; [M-Ac-H]-@6.95	ME189829	0.99	0.90	0.98	1.04	1.03
PG 34:1; [M-H]-@5.82	ME189868	1.03	0.90	0.94	1.02	1.04
PC 36:3; [M-Ac-H]-@6.39	ME189833	0.86	1.09	0.62	0.85	1.24
PG 36:0; [M-H]-@6.89	ME189870	1.06	0.99	0.56	0.85	1.20
PC 30:0; [M-Ac-H]-@5.85	ME189821	1.01	1.00	0.57	0.95	1.14
plasmenyl-PE 32:0; [M-H]-@7.02	ME189902	0.99	1.05	0.56	0.89	1.17
PG 32:0; [M-H]-@5.77	ME189867	0.94	0.99	0.67	0.86	1.22
PS 44:10; [M-H]-@5.32	ME189898	1.05	0.97	0.68	0.86	1.18
PC 30:1; [M-Ac-H]-@5.41	ME189822	1.07	1.03	0.75	0.75	1.20
PC 36:4; [M-Ac-H]-@6.15	ME189834	1.02	1.02	0.80	0.90	1.10
PS 40:6; [M-H]-@5.88	ME189892	0.98	1.00	0.72	0.96	1.11
PE 35:0; [M-H]-@7.49	ME189851	1.14	0.92	0.74	0.88	1.12
PG 44:12; [M-H]-@4.49	ME189883	1.05	0.88	0.77	0.88	1.18
PC 40:4; [M-Ac-H]-@7.23	ME189842	0.69	1.04	0.75	0.97	1.22
PS 36:4; [M-H]-@5.31	ME189888	0.82	1.23	0.83	0.83	1.14
PI 36:4; [M-H]-@5.22	ME189884	1.18	0.74	0.98	1.21	0.89
PS 34:2; [M-H]-@5.30	ME189887	1.27	0.93	0.82	1.08	0.88
PG 38:6; [M-H]-@5.34	ME189877	1.11	0.82	0.84	1.16	0.95
PS 42:11; [M-H]-@4.37	ME189895	1.15	0.89	0.76	1.15	0.93
PC 42:8; [M-Ac-H]-@6.34	ME189847	1.07	0.70	0.78	1.05	1.13
PG 36:5; [M-H]-@5.03	ME189874	1.27	0.73	0.75	1.07	1.01
PS 42:7; [M-H]-@5.97	ME189896	1.16	0.74	0.87	1.01	1.07
PC 38:2; [M-Ac-H]-@7.30	ME189837	1.19	0.76	0.86	1.08	1.00
PG 40:6; [M-H]-@5.95	ME189878	1.16	0.73	0.90	1.10	1.01
PE 40:9; [M-H]-@5.49	ME189861	0.98	0.72	0.45	1.20	1.14
PE 41:6; [M-H]-@7.15	ME189862	0.81	0.95	0.56	1.31	1.00
PS 44:12; [M-H]-@4.67	ME189900	0.86	0.64	0.73	1.40	1.02
PC 44:12; [M-Ac-H]-@5.51	ME189848	0.90	0.82	0.67	1.37	0.95
PE 44:12; [M-H]-@5.63	ME189866	0.81	0.80	0.64	1.45	0.95
PE 36:5; [M-H]-@5.88	ME189853	0.99	0.85	0.68	1.27	0.96
PE 36:6; [M-H]-@5.37	ME189854	0.97	0.94	0.76	1.26	0.91
PE 42:9; [M-H]-@6.06	ME189864	0.74	0.88	0.90	1.35	0.95
PC 38:6; [M-Ac-H]-@5.98	ME189839	0.87	0.82	0.79	1.26	1.01
PC 40:6; [M-Ac-H]-@6.65	ME189844	0.79	0.90	0.79	1.25	1.02
CL 74:7; [M-2H](2-)@6.02	ME189803	0.69	1.20	1.10	1.11	0.95
PG 40:8; [M-H]-@4.64	ME189880	0.83	0.70	1.29	0.98	1.18
PC 42:6; [M-Ac-H]-@7.31	ME189846	0.73	0.86	1.10	1.18	1.05
PE 42:7; [M-H]-@6.92	ME189863	0.96	0.71	1.15	1.26	0.93

Factors:

F1	CRE:Cone Cre \| SEX:f
F2	CRE:Cone Cre \| SEX:m
F3	CRE:negative \| SEX:f
F4	CRE:negative \| SEX:m
F5	CRE:Rod Cre \| SEX:f

Data matrix